Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Other Non-Current Assets (2016 - 2025)

Surgery Partners' Other Non-Current Assets history spans 11 years, with the latest figure at $56.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 1.22% year-over-year to $56.8 million; the TTM value through Dec 2025 reached $56.8 million, down 1.22%, while the annual FY2025 figure was $56.8 million, 1.22% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $56.8 million at Surgery Partners, up from $40.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $169.1 million in Q3 2022 and bottomed at $36.0 million in Q2 2024.
  • The 5-year median for Other Non-Current Assets is $58.3 million (2021), against an average of $83.3 million.
  • The largest annual shift saw Other Non-Current Assets soared 236.18% in 2022 before it tumbled 71.9% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $59.1 million in 2021, then skyrocketed by 143.99% to $144.2 million in 2022, then fell by 28.36% to $103.3 million in 2023, then crashed by 44.34% to $57.5 million in 2024, then dropped by 1.22% to $56.8 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Other Non-Current Assets are $56.8 million (Q4 2025), $40.7 million (Q3 2025), and $38.1 million (Q2 2025).